Maven Securities LTD Invests $2.55 Million in Guardant Health, Inc. $GH

Maven Securities LTD bought a new position in Guardant Health, Inc. (NASDAQ:GH) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 25,000 shares of the company’s stock, valued at approximately $2,554,000.

Other hedge funds also recently made changes to their positions in the company. Alyeska Investment Group L.P. acquired a new position in Guardant Health during the 3rd quarter valued at approximately $114,421,000. Norges Bank acquired a new position in Guardant Health during the 4th quarter valued at approximately $128,499,000. Franklin Resources Inc. boosted its position in Guardant Health by 26.1% during the 3rd quarter. Franklin Resources Inc. now owns 2,926,315 shares of the company’s stock valued at $182,836,000 after purchasing an additional 606,368 shares during the period. Westfield Capital Management Co. LP acquired a new position in Guardant Health during the 4th quarter valued at approximately $55,073,000. Finally, Erste Asset Management GmbH boosted its position in Guardant Health by 48.3% during the 4th quarter. Erste Asset Management GmbH now owns 1,045,917 shares of the company’s stock valued at $106,781,000 after purchasing an additional 340,700 shares during the period. Institutional investors and hedge funds own 92.60% of the company’s stock.

Insider Activity at Guardant Health

In other Guardant Health news, CEO Amirali Talasaz sold 210,000 shares of the business’s stock in a transaction on Wednesday, May 20th. The stock was sold at an average price of $109.89, for a total transaction of $23,076,900.00. Following the completion of the transaction, the chief executive officer owned 1,886,504 shares in the company, valued at approximately $207,307,924.56. The trade was a 10.02% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helmy Eltoukhy sold 100,000 shares of the business’s stock in a transaction on Friday, June 5th. The stock was sold at an average price of $126.30, for a total value of $12,630,000.00. Following the transaction, the chief executive officer owned 2,012,919 shares of the company’s stock, valued at $254,231,669.70. This trade represents a 4.73% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 449,238 shares of company stock worth $51,164,492 in the last ninety days. 5.60% of the stock is currently owned by corporate insiders.

Guardant Health Stock Performance

Shares of GH stock opened at $131.62 on Monday. Guardant Health, Inc. has a 1 year low of $40.35 and a 1 year high of $134.28. The stock has a fifty day moving average of $103.51 and a two-hundred day moving average of $102.08. The firm has a market capitalization of $17.45 billion, a PE ratio of -38.83 and a beta of 1.61.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Raymond James Financial restated an “outperform” rating and set a $129.00 price objective on shares of Guardant Health in a research report on Monday, February 23rd. JPMorgan Chase & Co. boosted their price objective on Guardant Health from $130.00 to $135.00 and gave the company an “overweight” rating in a research report on Friday, May 8th. Evercore upgraded Guardant Health from an “in-line” rating to an “outperform” rating and set a $160.00 price objective for the company in a research report on Tuesday, June 2nd. Citigroup boosted their price objective on Guardant Health from $135.00 to $150.00 and gave the company a “buy” rating in a research report on Friday, February 20th. Finally, TD Cowen restated a “buy” rating on shares of Guardant Health in a research report on Thursday, May 21st. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Guardant Health currently has a consensus rating of “Moderate Buy” and a consensus target price of $141.95.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.